UCB cuts price, extends €1bn revolver
Belgian pharmaceutical firm UCB has become the latest western European firm to reduce the cost of its bank debt, after closing an amend-and-extend agreement on a €1bn revolving credit facility.
The maturity of the facility has been moved from 2016 to 2019, with two one year extension options.
UCB is paying less for the new loan than it was for the existing deal, according to the company.
The borrower began speaking to its core relationship banks at the end of
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: firstname.lastname@example.org or find out more online here.